SCM
TVTX icon

Sterling Capital Management’s Travere Therapeutics TVTX Stock Holding History

Sterling Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Sell
314
-360
-53% -$16K ﹤0.01% 1940
2026
Q1 		$20K Sell
674
-132
-16% -$3.95K ﹤0.01% 2027
2025
Q4 		$30.8K Buy
806
+221
+38% +$7.19K ﹤0.01% 2005
2025
Q3 		$14K Buy
585
+234
+67% +$4.4K ﹤0.01% 2319
2025
Q2 		$5.2K Sell
351
-1,100
-76% -$18.2K ﹤0.01% 2496
2025
Q1 		$26K Sell
1,451
-910
-39% -$18.5K ﹤0.01% 1583
2024
Q4 		$41.1K Buy
2,361
+2,115
+860% +$37.4K ﹤0.01% 1667
2024
Q3 		$3.44K Buy
+246
New +$2.56K ﹤0.01% 1922

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's TVTX Position: Q2 2026 in Review

Sterling Capital Management reduced its Travere Therapeutics (TVTX) stake by 53% in Q2 2026, selling an estimated $16K and leaving 314 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1940.

Sterling Capital Management first reported a position in TVTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $41.1K in Q4 2024. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Sterling Capital Management held 314 shares of Travere Therapeutics worth $17.8K as of Q2 2026.
  • Sterling Capital Management sold 360 Travere Therapeutics shares in Q2 2026, an estimated $16K.
  • Travere Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1940 holding.
  • Sterling Capital Management first reported a position in Travere Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Travere Therapeutics position peaked at $41.1K in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.